Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases

摘要: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced to BMPs, especially BMP-9. compositions described herein can be used prepare ActRIIB ligand trap proteins, modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood neuronal tissue counteract muscle wasting, bone loss, anemia, inflammation fibrosis in a therapeutically meaningful manner. Because these next-generation myostatin/activin inhibitors are safer more effective molecules than currently available inhibitors, they useful wide variety clinical indications.